Garrett Rappazzo

Company: Adimab LLC

Job title: Scientist

Seminars:

Rapid engineering of soluble T cell receptors for enhanced affinity via a high-throughput yeast-based platform 9:20 am

• Soluble T cell receptor (TCR)-based CD3 bispecific therapeutics can co-opt T cell function to eradicate virally infected and cancerous cells via peptide-HLA (pHLA) recognition. • Native TCRs require extensive affinity maturation for efficacy in clinically validated CD3 bispecific formats, posing a significant barrier to the development of soluble TCR-based therapeutics. • Adimab has developed…Read more

day: Conference Day Two